Merck Begins Clinical Trials on Gardasil 9 Single-Dose Regimen
Wednesday, 13 March 2024, 09:59
Merck Initiates Study on Single-Dose Regimen for HPV Vaccine Gardasil 9
Merck has announced that it will be conducting clinical trials to evaluate the efficacy and safety of a single-dose regimen for its HPV vaccine, Gardasil 9. The study aims to determine if a one-dose schedule can offer adequate protection against HPV infections, competing with the established two-dose regimen.
Key Points:
- Merck is exploring the possibility of simplifying the vaccination process for HPV.
- Gardasil 9 could potentially provide significant protection with just one dose.
- This move may have implications for future immunization strategies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.